Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences
10.1016/j.jse.2020.08.028 30 FukaiT.Ushio-FukaiM
Missed tirzepatide doses are unlikely to cause dangerously low blood sugar in most weight loss patients, but those with diabetes should monitor blood glucose carefully and contact their doctor
FASEB, 1981
Side Effects and Safety Both medications are generally tolerated, but their side-effect profiles differ in line with how they work
US$ 20.46
US$ 22.26
US$ 22.99
US$ 22.53
US$ 21.69
US$ 21.66
US$ 25.52
